Sciclone Pharmaceuticals (NASDAQ:SCLN)($6.79) – and its partner BTG plc (LSE: BTG), today announced, that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularized tumors. BTG and SciClone previously entered into […]
A commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. INSY announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), the […]